"Food noise" is the colloquial term for the persistent, intrusive thoughts about food that drive snacking, grazing, and the feeling that food is always on your mind. The term wasn't coined by clinicians — it came from patients describing the most striking effect of GLP-1 agonist therapy. Researchers have since adopted it.
The neuroscience behind it
Food noise lives at the intersection of homeostatic hunger (your body's caloric-deficit signaling) and hedonic hunger (your brain's reward and craving circuitry). The arcuate nucleus, ventral tegmental area, nucleus accumbens, and amygdala all participate. GLP-1 receptors are present in all of them.
When GLP-1 agonists activate those receptors, two things happen: the homeostatic hunger signal becomes less intense, and the reward valence of food drops. Patients describe this as "I can see the cookie on the counter and just not care."
What patients actually report
- Mealtime becomes less anticipatory — food shows up in your day rather than being the structure of it
- Grocery shopping requires planning, because hunger-driven impulse purchases stop happening
- Restaurant menus feel different — the want of specific dishes is quieter
- Some patients report a flattening of food enjoyment too, not just craving
Food noise is not the same as appetite
Appetite — the physical sensation of hunger — also drops on GLP-1, but it's a different effect. You can be hungry without food noise (think: skipping lunch and being aware of it without obsessing). You can have food noise without acute hunger (think: thinking about ice cream at 10 PM while still full from dinner).
It comes back when you stop
Food noise reliably returns within weeks of discontinuation. This is one of the strongest qualitative arguments patients make for staying on maintenance dosing. See our coming-off-GLP-1 guide.
Implications for addiction research
The same hedonic circuits affected by GLP-1 are central to substance-use disorders. Emerging research is examining GLP-1 agonists for alcohol use disorder, nicotine dependence, and pathological gambling. See our blog post on GLP-1 and alcohol use.
NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.